MLH1 methylation has been indicated not only as a diagnostic biomarker and an indicator of good prognosis in several cancers, including colorectal, ovarian, and breast cancers, but also as a therapy response biomarker associated with platinum compounds, temozolomide, and epirubicin resistance and with methotrexate sensitivity [60]. The gene discussed is MLH1; the disease is breast cancer.